目的：探讨基底样乳腺癌（BLBC）与三阴性乳腺癌（TNBC）的临床病理特征、免疫组织化学染色及二者间的关系和诊断标准。方法采用免疫组化法从1003例乳腺癌中筛选出135例 TNBC，再根据其表皮生长因子受体（EGFR）、CK5/6表达情况，从 TNBC 中筛选出 BLBC 及非 BLBC，研究其临床病理特征差异及 Ki67的表达情况。结果135例 TNBC 患者中106例表达 EGFR、CK5/6中的至少1项免疫表型（即 BLBC），29例两者均不表达（即非 BLBC）。两组患者年龄、肿瘤大小、淋巴结是否转移及组织学类型比较差异未见统计学意义（P >0.05），两组 Ki67的表达比较差异有统计学意义（P <0.05）。结论 TNBC 与 BLBC 有交叉但又不完全重叠，CK5/6、EGFR是筛选 BLBC 的有效指标，Ki67是乳腺癌患者的独立预后指标。%Objective To investigate the clinicopathologic and immunohistochemical features of basal-like breast carcinoma(BLBC)and triple negative breast carcinoma(TNBC),and the relationship between them and the diagnosis standard. Methods One hundred and thirty-five cases of TNBC were screened from 1 003 cases of breast cancer by immunohistochemical method,and then BLBC and non-BLBC cases were identified from TNBC cases according to the expression of EGFR,CK5 / 6 expression. Their clinicopathological features and the expression of Ki67 were analyzed. Results One hundred and six cases expressed at least one phenotype markers(CK5 / 6,EGFR)in the 135 TNBC patients (BLBC),neither of them expressed in 29 cases(non BLBC),there was no significant difference in age, tumor size,lymph node metastasis or histological type between the two groups(P > 0. 05). The Ki67 expression between the two groups was significant(P < 0. 05). Conclusions The cases of BLBC and TNBC mostly cross with each other but not overlap completely. CK5 / 6,EGFR can be used as effective markers for screening BLBC cases. Ki67 is an independent prognostic factor in breast cancer patients.
展开▼
